Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism.

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism.

Abstract: The present invention relates to a method for preventing, reducing the progression of, and treating Alzheimer disease (AD), by creating delipidated protein particles and lipoprotein particles including at least one of LDL, VLDL, or HDL, other particles associated with lipid transport and metabolism, and combinations thereof, and administering these delipidated particles to patients at risk of developing AD or patients diagnosed with AD. The present invention employs energy and solvents useful for extracting lipids and cholesterol from the lipid-containing plasma and forming delipidated protein particles and lipoprotein particles. The present invention uses optimal solvent systems such that the lipid is dissolved while other plasma proteins are relatively intact. The present invention also provides a method of combining plasma delipidation and particle administration with other therapeutic interventions for prevention and treatment of AD.

Abstract: An extracorporeal fluid treatment apparatus which is selectively operable in a disinfecting mode or a treatment mode includes an inlet line, a pre-treatment portion, an input pump, a heater, an input shunt, a filtration device, a post-treatment portion, a drain line and an output shunt. The apparatus also includes a combination of valves which are selectively positionable in disinfecting mode to create an input fluid circuit which includes the pre-treatment portion and the input shunt, and which is in fluid isolation from the post-treatment portion and from the filtration device. In disinfecting mode, the valves are also selectively positionable to create an output fluid circuit which includes the post-treatment portion and the output shunt, and which is in fluid isolation from the pre-treatment portion and from the filtration device.

Abstract: A stable, shippable microbicidal composition including between about 0.2 to 8% hydrogen peroxide, about 0.2 to 11% peracetic plus acetic acid, 0 to about 1.0% sequestrant such as organic phosphonic acid or its salt and water, and surfactant between 0 and about 1% with the ratio of total acid to H.sub.2 O.sub.2 being between about 1.0 and 11.

Abstract: An extracorporeal fluid treatment apparatus which is selectively operable in a disinfecting mode or a treatment mode includes an inlet line, a pre-treatment portion, an input pump, a heater, an input shunt, a filtration device, a post-treatment portion, a drain line and an output shunt. The apparatus also includes a combination of valves which are selectively positionable in disinfecting mode to create an input fluid circuit which includes the pre-treatment portion and the input shunt, and which is in fluid isolation from the post-treatment portion and from the filtration device. In disinfecting mode, the valves are also selectively positionable to create an output fluid circuit which includes the post-treatment portion and the output shunt, and which is in fluid isolation from the pre-treatment portion and from the filtration device.

Abstract: A method and apparatus for cleaning of a dialysate circuit located downstream of the dialyzer in a dialysis machine is described. The method comprises injecting a cleaning agent into the dialysis machine at a point between the dialyzer inlet port and the downstream dialysate circuit in an amount sufficient to substantially reduce the deposit in said downstream dialysate circuit; permitting flow of the agent towards the downstream dialysate circuit; and substantially preventing flow of the agent toward the dialyzer inlet port. The injection adaptor apparatus comprises an injection connector downstream of a backflow prevention valve, and two flanking tubing connectors. The apparatus is inserted at a point downstream of the dialyzer inlet port, and cleaning agent is injected into the injection connector. An adaptor to facilitate handling of cleaning agent during manual agent injection is also described. Additionally, an automated agent injection apparatus is described.

Abstract: An improved dialysis apparatus and method wherein a dialysis delivery system delivers dialysate to a dialyzer through an external dialysate line with a dialyzer inlet connector and a dialysate waste system removes spent dialysate from the dialyzer through an external spent dialysate line with a dialyzer outlet connector. A bypass block comprises a first bypass block connector adapted to connect to the dialyzer inlet connector and a second bypass block connector adapted to connect to the dialyzer outlet connector and a conduit interconnecting the first bypass block connector and the second bypass block connector with a check valve located intermediate the first and second bypass block connectors and oriented to permit fluid flow only from the first bypass block connector to the second bypass block connector.

Abstract: A stable, shippable microbicide solution, having improved anticorrosive properties comprising a two part system, the first part consists of a mixture of acetic acid, hydrogen peroxide, peracetic acid, and water. This is referred to for brevity as a peroxide/peracid solution. The second consists of water having dissolved therein a wetting agent which is preferably Victawet.RTM. 35B which is the sodium hydroxide reaction product of an aliphatic alcohol and phosphorous pentoxide. Three other Victawet.RTM. agents have proven operative. Alternatively, Fluorad.TM. FC95, which is a agent of potassium perfluoroalkyl sulfonates may be used. The microbicide may also be a premixed one component system containing the anticorrosive agents of the invention.

Abstract: A machine for reprocessing catheters of the type having a double lumen, one of which leads to a balloon. A used catheter is sealed within a cassette which in turn is connected by multiple ports to a cleaning side of the machine. Cleaning solution is flushed through the inside and outside of the catheter. The balloon integrity is tested by adding step wise volume additions and monitoring the pressure. The data generated is compared to a standard curve for new catheters. The cleaned, sterile catheter is then rinsed to remove all traces of sterilant. Sterile saline is alternatively flushed through the cassette and catheter. The balloon is again tested for leaks. No portion of the rinse side of the machine requires sterilizing except for the disposable tubing set and saline source. The rinsed, clean and sterile catheter is removed from the cassette for reuse.